Nkarta prices upsized $200 mln equity offering; shares slip

Nkarta

26/04/2022 11:38

** Nkarta Inc's  NKTX.O  shares down 6.3% at $17.54
premarket after co raises more equity than targeted
    ** Cell therapy developer late Mon priced ~13.3 mln share
offering at $15 with Cowen, SVB Securities and Evercore acting
as jt bookrunners  urn:newsml:reuters.com:*:nGNX75pXrp
    ** Co launched $150 mln equity offering after its stock on
Mon soared 141% to $18.72 on promising early data from its
drugs, NKX101 and NKX019, in patients with different blood
disorders  urn:newsml:reuters.com:*:nL2N2WN2AR  urn:newsml:reuters.com:*:nL3N2WN257
    ** The drugs were well tolerated, with no reports of side
effects associated with CAR-T cell therapies, such as cytokine
release syndrome or graft versus host disease, co said
    ** NKTX, which went public in 2020 IPO priced at $18,
had$219 mln of cash as of Mar 31, 2022, per offering prospectus
filing https://www.sec.gov/Archives/edgar/data/1787400/000119312522117512/d314534d424b5.htm

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-332-219-1430))